Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
351 studies found for:    Open Studies | antidepressants
Show Display Options
Rank Status Study
21 Recruiting Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth
Conditions: Depression;   Anxiety;   Bipolar Disorder
Interventions: Drug: Escitalopram;   Behavioral: Cognitive behavioral Psychotherapy
22 Recruiting A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Condition: Treatment-resistant Depression
Interventions: Drug: Esketamine (Intranasal Spray);   Drug: Duloxetine (Oral Antidepressant);   Drug: Escitalopram (Oral Antidepressant);   Drug: Sertraline (Oral Antidepressant);   Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
23 Recruiting SSRIs vs. TCAs for Depression in ALS Patients
Conditions: Depression;   Amyotrophic Lateral Sclerosis
Interventions: Drug: Tricyclic Antidepressants ("TCA");   Drug: Selective Serotonin Uptake Inhibitors ("SSRI")
24 Recruiting Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Conditions: Depression;   Antidepressant Drug Adverse Reaction
Interventions: Drug: SSRI treated group;   Drug: non-SSRI treated group
25 Recruiting CAP-Ketamine for Antidepressant Resistant PTSD
Conditions: PTSD;   Posttraumatic Stress Disorder
Interventions: Drug: Ketamine;   Drug: Placebo
26 Recruiting Mechanisms of Antidepressant Non-Response in Late-Life Depression
Condition: Major Depressive Disorder
Intervention: Drug: Escitalopram
27 Not yet recruiting A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia
Conditions: Depression;   Major Depressive Disorder;   MDD;   Insomnia
Interventions: Drug: suvorexant;   Drug: Placebo
28 Recruiting Predict Antidepressant Responsiveness Using Pharmacogenomics
Conditions: Depression;   Depressive Symptoms
Interventions: Drug: SSRI treated group;   Drug: non-SSRI treated group
29 Recruiting The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
Conditions: Major Depressive Disorder;   Bipolar Disorder
Interventions: Other: chronobiological augmentation;   Drug: sertraline, lithium;   Radiation: one night of sleep deprivation and two FDG PET scans
30 Recruiting Antidepressant Effects of Ayahuasca
Condition: Major Depression
Interventions: Drug: Ayahuasca;   Drug: placebo
31 Recruiting the Antidepressant Effect of rTMS as add-on to ECT
Condition: Depression
Interventions: Device: Right prefrontal Low frequency (1 hz) rTMS,;   Device: Sham-rTMS
32 Not yet recruiting Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression
Condition: Treatment Resistant Major Depressive Disorder Depression
Interventions: Drug: Aripiprazole;   Device: Repetitive transcranial magnetic stimulation (rTMS);   Drug: Venlafaxine XR
33 Not yet recruiting Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression
Conditions: Depression;   Major Depressive Disorder
Interventions: Dietary Supplement: CocoaVia;   Other: Placebo
34 Recruiting Connectivity Affecting the Antidepressant REsponse Study
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Bupropion XL
35 Recruiting Cytochrome P450-2D6 Screening Among Elderly Using Antidepressants (CYSCE)
Conditions: Depression;   Depressive Disorder;   Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant;   Intermediate Metabolizer Due to Cytochrome P450 CYP2D6 Variant;   Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Intervention: Other: Genotype information accompanied by a drug dosing advice
36 Not yet recruiting The Antidepressant Efficacy of Low Frequency rTMS as add-on
Condition: Depression
Interventions: Device: Right prefrontal low frequency rTMS;   Other: Sham-rTMS
37 Not yet recruiting Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD)
Conditions: COPD;   Anxiety;   Depression;   Stress
Interventions: Drug: Sertraline;   Drug: Placebo
38 Recruiting Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
Condition: Major Depression
Interventions: Drug: AV 101 (4-Chlorokynurenine);   Other: Placebo
39 Recruiting Advancing Personalized Antidepressant Treatment Using PET/MRI
Condition: Depression
Interventions: Drug: Escitalopram;   Drug: Placebo
40 Recruiting Identification of Genetic Markers and Predictors of Antidepressant-induced Suicidality in Youth Depression
Conditions: Depression;   Suicidal Ideation
Intervention: Drug: bupropion or lamotrigine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.